GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ICON Public
ICON is one of the world's largest contract research organizations (CROs), managing clinical trials for pharmaceutical companies. Its stock price reflects the trend toward outsourcing R&D in the pharmaceutical industry, which ensures a stable flow of orders and growth.
Share prices of companies in the market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial services to pharmaceutical companies. We classify it as a pharmaceutical testing company. The chart below shows the dynamics of this sector, driven by R&D outsourcing.
Broad Market Index - GURU.Markets
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial services to pharmaceutical and biotech companies. As a key partner for the pharmaceutical industry, it is included in the GURU.Markets index. The chart below shows the overall market performance. Compare its stock price to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ICLR - Daily change in the company's share price ICON Public
The daily price change for ICON, a major contract research organization, reflects its response to the volume of clinical trials in the pharmaceutical industry. While the chart of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma tests
ICON Public Limited Company is one of the world's largest contract research organizations (CROs). This chart shows the average daily volatility of the healthcare sector. Compared to the dynamics of ICLR, whose revenue depends on pharmaceutical companies' R&D budgets, it becomes a barometer of innovation.
Daily change in the price of a broad market stock, index - GURU.Markets
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial services. Its business serves as a barometer of activity in the global pharmaceutical industry. The chart below shows general market fluctuations, which can be used to assess the sector's stability.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ICON Public
ICON is one of the world's largest contract research organizations (CROs). Its annual growth rate serves as a barometer of R&D investment in the pharmaceutical and biotech industries. The chart below tells the story of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Pharma tests
ICON Public Limited Company is one of the world's largest contract research organizations (CROs), providing services to the pharmaceutical and biotechnology industries. Its scale and global reach make it a key partner in drug development. The chart below shows how its leadership influences its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ICON is one of the world's leading contract research organizations (CROs), helping pharmaceutical companies conduct clinical trials. The company's growth is fueled by increasing R&D spending in the pharmaceutical industry, making its business resilient to economic cycles and allowing it to consistently outperform the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ICON Public
The value of ICON, a leading contract research organization (CRO), depends on the pharmaceutical industry's R&D budgets. The monthly fluctuations on the chart reflect the demand for clinical trial outsourcing from large pharmaceutical and biotech companies, which drives steady growth.
Monthly dynamics of market capitalization of the market segment - Pharma tests
ICON Public Limited Company is one of the world's largest contract research organizations (CROs), helping pharmaceutical and biotech companies conduct clinical trials. Its sector dynamics, shown in the graph, reflect the volume of R&D. This allows one to assess how ICON's global scale and technological platform help accelerate the development of new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ICON is one of the world's largest contract research organizations (CROs) serving the pharmaceutical industry. Demand for its services is stable, as drug development is ongoing. The chart below allows you to assess whether this business model has allowed ICON shares to be more resilient to market fluctuations than the broader index.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ICON Public
The short-term performance of ICON, a major contract research organization, is a barometer for the pharmaceutical industry. News about clinical trial outsourcing by Big Pharma and the level of funding in the biotech sector directly impact its future revenue.
Weekly dynamics of market capitalization of the market segment - Pharma tests
ICON and the entire contract research organization (CRO) sector depend on the overall R&D spend in the pharmaceutical industry. The trend toward clinical trial outsourcing is a tailwind for everyone. The chart shows how the market leader is leveraging these industry opportunities.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ICON is one of the world's largest contract research organizations (CROs). It benefits from the trend toward R&D outsourcing in the pharmaceutical industry. The chart shows how this consistent growth allows its shares to outperform both the market and the healthcare sector.
Market capitalization of the company, segment and market as a whole
ICLR - Market capitalization of the company ICON Public
ICON's market capitalization chart is a financial valuation of one of the world's largest players in the clinical research organization (CRO) market. It reflects the scale of the company's outsourcing services to pharmaceutical and biotech giants. Its dynamics serve as a barometer of investment in drug development in the global pharmaceutical industry.
ICLR - Share of the company's market capitalization ICON Public within the market segment - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing drug development and commercialization services. Its market capitalization is enormous, reflecting its leadership in clinical trial outsourcing for pharmaceutical companies.
Market capitalization of the market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs) providing services to the pharmaceutical industry. The chart below shows the total market capitalization of this entire sector. Its growth reflects the trend toward clinical trial outsourcing. ICON's scale allows it to be a strategic partner for major pharmaceutical companies.
Market capitalization of all companies included in a broad market index - GURU.Markets
Clinical trials, the foundation of new drug development, are a massive industry, as reflected in the graph. ICON is one of the world's largest contract research organizations (CROs). Its market capitalization reflects the trend toward R&D outsourcing by pharmaceutical giants.
Book value capitalization of the company, segment and market as a whole
ICLR - Book value capitalization of the company ICON Public
For ICON, a clinical research giant, this chart represents the physical foundation for drug development. The growth in book value reflects the expansion of its global network of laboratories, offices, and technology platforms. This physical infrastructure enables testing for pharmaceutical companies worldwide.
ICLR - Share of the company's book capitalization ICON Public within the market segment - Pharma tests
As a global contract research organization, ICON possesses significant physical infrastructure. Its sector assets include laboratories, clinics, and operational centers worldwide. This physical base enables it to manage complex clinical trials for the entire pharmaceutical industry.
Market segment balance sheet capitalization - Pharma tests
ICON Public is a contract research organization (CRO) that helps pharmaceutical companies conduct clinical trials. Their assets include laboratories and offices around the world. The chart below shows their facilities, which are smaller than those of manufacturers but essential for scientific research.
Book value of all companies included in the broad market index - GURU.Markets
ICON's physical infrastructure is a global network of clinical laboratories and offices, providing the physical infrastructure for clinical trials. The chart below shows how the company has expanded its presence to help bring new drugs to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ICON Public
ICON, like other CROs, has laboratories and offices. But its true value lies in its scale, reputation, and ability to conduct global clinical trials. The chart below shows how the market valued its leadership in pharmaceutical outsourcing.
Market to book capitalization ratio in a market segment - Pharma tests
ICON is a major contract research organization providing services to the pharmaceutical industry. Its value lies in its expertise and scale. The chart shows the market premium it places on its role in drug development, comparing its market capitalization to its physical assets.
Market to book capitalization ratio for the market as a whole
ICON Public is one of the world's largest contract research organizations (CROs) providing services to the pharmaceutical industry. Its key assets are its global reach, data, and experience. Unlike the average valuation in this chart, ICON's market capitalization is built on its ability to support drug discovery, a critical service.
Debts of the company, segment and market as a whole
ICLR - Company debts ICON Public
ICON, a major contract research organization (CRO), is using a growth-through-acquisition strategy to expand its services to the pharmaceutical industry. This chart shows how the company is using debt financing to acquire competitors and build a global platform for end-to-end clinical trials.
Market segment debts - Pharma tests
ICON plc is one of the world's largest contract research organizations (CROs), providing drug development and commercialization services. Growth in this sector often occurs through acquisitions. This chart shows how ICON's financial strategy reflects its commitment to being a one-stop-shop for the pharmaceutical industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ICON Public
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services. This chart shows its debt load, which may have increased due to industry consolidation. The business relies on R&D spending in the pharmaceutical industry, and a reduction in these budgets is a key risk.
Market segment debt to market segment book capitalization - Pharma tests
ICON is one of the world's largest contract research organizations (CROs), supporting clinical trials for pharmaceutical companies. This outsourcing business is growing alongside R&D spending in the pharmaceutical industry. The chart shows debt trends in the sector, providing insight into the financial environment in which ICON competes.
Debt to book value of all companies in the market
ICON is one of the largest CROs in the world. Its business is less capital-intensive than that of pharmaceutical companies, but requires investment in personnel and technology. This chart shows the average debt across the economy, allowing one to assess how ICON's service-based financial structure differs from other sectors.
P/E of the company, segment and market as a whole
P/E - ICON Public
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to the pharmaceutical and biotech industries. This chart shows investor sentiment on the growing trend of R&D outsourcing. High values ββreflect stable demand for drug development services.
P/E of the market segment - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical and biotech companies. They help bring new drugs to market. This chart shows the average rating for the pharmaceutical trials sector, reflecting the volume of investment in drug development.
P/E of the market as a whole
ICON plc is a global contract research organization (CRO) providing outsourced development services to the pharmaceutical and biotech industries. This chart shows the overall sentiment in the healthcare sector, but for ICLR, R&D investment is more important. A company's valuation is an indicator of its drug development activity.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ICON Public
ICON is one of the world's largest contract research organizations (CROs), providing drug development and commercialization services. This chart reflects expectations for R&D outsourcing in the pharmaceutical industry. Its trend predicts that pharmaceutical companies will increasingly outsource clinical trials to improve efficiency.
%20P%2FE%20ICON%20Public&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ICON-Public&v=1772581305572 "Chart of the company's future (projected) P/E ICON Public"){kind=icon}
Future (projected) P/E of the market segment - Pharma tests
ICON is a global contract research organization (CRO) that helps pharmaceutical and biotech companies conduct clinical trials. This chart shows the company's estimated future revenue in the context of the healthcare sector. It illustrates how investors view its scale and performance following major acquisitions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-tests&v=1772581305610 "Future (projected) P/E graph of the market segment - Pharma tests")
Future (projected) P/E of the market as a whole
ICON Public is one of the world's largest contract research organizations (CROs), providing services to the pharmaceutical and biotech industries. This chart, reflecting investor appetite for the biotech sector, is important to ICON. The ease with which pharmaceutical companies can raise capital directly impacts their R&D budgets and, consequently, the demand for ICON's outsourcing services.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772581305643 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ICON Public
ICON plc is one of the world's leading contract research organizations (CROs), providing outsourced drug development services to the pharmaceutical industry. The company's growth is driven by the trend toward outsourcing clinical trials. This chart shows the financial performance of a business that helps bring new drugs to market.
Profit of companies in the market segment - Pharma tests
ICON is a global contract research organization (CRO) that helps pharmaceutical and biotech companies conduct clinical trials. This chart shows profitability in the pharmaceutical services sector. For ICLR, it's an indicator of drug R&D activity, which drives drug growth.
Overall market profit
ICON Public is one of the world's leading contract research organizations (CROs). The company helps pharmaceutical and biotech companies conduct clinical trials. Its success depends on outsourcing R&D to the pharmaceutical industry. While this graph of overall corporate profitability is important, the volume of investment in drug development is even more important.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ICON Public
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical companies. The revenue forecast presented here reflects expectations for R&D spending in the pharmaceutical industry. Major contracts and the integration of recent acquisitions are the focus of analysts.
%20profit%20of%20the%20company%20ICON%20Public&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ICON-Public&v=1772581305894 "Graph of future (projected) profit of the company ICON Public"){kind=icon}
Future (predicted) profit of companies in the market segment - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical companies. Profit forecasts for this sector depend on pharmaceutical R&D budgets. This chart shows the analysts' collective view on the future of drug development outsourcing, a key trend in the industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-tests&v=1772581305970 "Graph of future (predicted) profits of companies in a market segment - Pharma tests")
Future (predicted) profit of the market as a whole
ICON is one of the world's largest contract research organizations (CROs), supporting clinical trials. Its growth depends on investment in pharmaceutical R&D. The total revenue forecasts in this chart reflect the overall investment climate, which determines pharmaceutical companies' willingness to initiate new research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772581305998 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ICON Public
ICON Public is one of the world's largest contract research organizations (CROs), providing outsourcing services to the pharmaceutical industry. This chart shows how highly investors value its revenue. The steadily rising costs of drug development are driving pharmaceutical companies to increasingly turn to CROs, providing ICON with a steady stream of orders.
P/S market segment - Pharma tests
ICON plc is one of the world's largest contract research organizations (CROs), providing outsourced development and clinical trials services to the pharmaceutical and biotech industries. This chart shows the industry average price-to-sales ratio. It helps understand how the market perceives ICON's scale and its key role in bringing new drugs to market.
P/S of the market as a whole
ICON plc is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical and biotech companies. Its revenue is driven by its R&D activity. This chart provides a market-wide perspective on investor sentiment toward the medical innovation sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ICON Public
ICON is one of the world's largest contract research organizations (CROs), helping pharmaceutical companies conduct clinical trials. This chart shows how investors estimate the company's future revenue. It is an indicator of the level of investment in drug development globally.
%20P%2FS%20ICON%20Public&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ICON-Public&v=1772581306111 "The graph of the company's future (projected) P/S ICON Public"){kind=icon}
Future (projected) P/S of the market segment - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing outsourced drug development services to the pharmaceutical industry. Its scale allows it to conduct global clinical trials. This chart reflects how the market views its leadership position and its ability to benefit from the R&D outsourcing trend.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20tests&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-tests&v=1772581306134 "Future (projected) P/S market segment graph - Pharma tests")
Future (projected) P/S of the market as a whole
ICON Public is a global contract research organization (CRO) providing clinical trial outsourcing services to the pharmaceutical industry. Their growth depends on their clients' R&D budgets. This market optimism is important to ICON. Influxes of investment into biotech during growth periods allow their clients to launch more clinical programs, increasing demand for their services.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772581306158 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ICON Public
ICON is one of the world's leading contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical and biotech companies. This chart illustrates the dynamics of R&D in the pharmaceutical industry. Revenue growth is directly related to the volume and complexity of the clinical trials that clients outsource to ICON.
Sales of companies in the market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs). They help pharmaceutical and biotech companies conduct clinical trials of new drugs, managing complex processes globally. Their revenue structure reflects revenue from providing these comprehensive services across all phases of drug development.
Overall market sales
ICON is one of the world's leading contract research organizations (CROs). It helps pharmaceutical and biotech companies conduct clinical trials of new drugs, accelerating their time to market. This total revenue chart includes the healthcare sector, where ICON plays a key role in the ecosystem for developing innovative treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ICON Public
ICON Public is one of the world's largest contract research organizations (CROs), helping pharmaceutical and biotech companies conduct clinical trials. This chart reflects revenue forecasts, which are driven by R&D investment in the global pharmaceutical industry and the trend toward clinical trial outsourcing.
%20sales%20of%20the%20company%20ICON%20Public&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ICON-Public&v=1772581306239 "Schedule of future (projected) sales of the company ICON Public"){kind=icon}
Future (projected) sales of companies in the market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs), providing outsourced drug development and clinical trials services. This chart shows R&D spending forecasts for the global pharmaceutical industry. It reflects how aggressively pharmaceutical companies will invest in new drugs by outsourcing their clinical trials to ICON.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-tests&v=1772581306253 "Schedule of future (projected) sales of companies in the market segment - Pharma tests")
Future (projected) sales of the market as a whole
ICON Public is a global contract research organization (CRO) providing clinical trial outsourcing services. This chart, which reflects investment forecasts in the pharmaceutical and biotech industries, is important to ICON. Growing R&D budgets in the industry directly drives demand for the company's clinical trial services.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772581306296 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ICON Public
ICON is a global contract research organization (CRO) providing drug development and commercialization services. This chart shows its profitability. Profitability depends on the outsourcing budgets of pharmaceutical and biotech companies. Its scale of operations and expertise in conducting complex clinical trials are its key advantages.
Market segment marginality - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing outsourced development and clinical trials services to the pharmaceutical industry. Profitability depends on the scale of operations and the ability to effectively manage global research. This chart demonstrates the company's operational strength. Outperforming competitors indicates leadership.
Market marginality as a whole
ICON is one of the world's largest contract research organizations (CROs), providing clinical research outsourcing services to pharmaceutical companies. Its growth is fueled by the trend toward R&D outsourcing. This overall profitability chart reflects the health of ICON's clients, but the structural growth of the industry is a more important driver.
Employees in the company, segment and market as a whole
Number of employees in the company ICON Public
ICON is one of the world's largest contract research organizations (CROs), providing clinical development outsourcing services to the pharmaceutical industry. This chart shows a massive global team of scientists, physicians, and managers who help pharmaceutical companies conduct clinical trials, accelerating the time new drugs reach the market.
Share of the company's employees ICON Public within the market segment - Pharma tests
ICON Public is one of the world's largest contract research organizations (CROs), providing outsourced drug development services to the pharmaceutical industry. This chart shows its global scientific and operational reach. It reflects the significant share of physicians, scientists, and clinical trial managers worldwide that ICON employs.
Number of employees in the market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs), managing clinical trials for pharmaceutical companies. Outsourcing R&D has become the norm in the industry. This chart shows a global team of scientists and managers who help accelerate the development and launch of new drugs, making medicine more efficient.
Number of employees in the market as a whole
ICON Public is one of the world's leading contract research organizations (CROs), providing drug development outsourcing services to the pharmaceutical and biotech industries. Its business depends on investment in R&D. The growth in overall employment, reflected in this chart, signals a healthy economy where investors and large pharmaceutical companies are willing to fund clinical trials and outsource them to ICON.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ICON Public (ICLR)
ICON Public is one of the world's largest contract research organizations (CROs). This chart illustrates a model based on human capital. Low capitalization per employee is typical for this business, where revenue is directly dependent on the number of scientists and specialists conducting clinical trials for pharmaceutical clients.
%20of%20the%20company%20ICON%20Public%20(ICLR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ICON-Public-ICLR&v=1772581306528 "Chart of market capitalization per employee (in thousands of dollars) of the company ICON Public (ICLR)"){kind=icon}
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma tests
ICON Public (ICLR) is one of the world's largest contract research organizations (CROs). Like Medpace, it is a service business managing clinical trials for pharmaceutical companies. This chart shows the industry average, measuring the market value generated by each of ICON's thousands of R&D professionals.
%20by%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-tests&v=1772581306549 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma tests")
Market capitalization per employee (in thousands of dollars) for the overall market
ICON is one of the world's largest contract research organizations (CROs), supporting clinical drug trials. In this service industry, the company's per-employee market cap is a measure of reputation and effectiveness. It reflects how the market evaluates ICON's ability to manage complex global studies for major pharmaceutical companies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772581306677 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ICON Public (ICLR)
ICON is one of the world's largest CROs helping pharmaceutical companies conduct clinical trials. Like Medpace, it's a business built on the expertise of thousands of people. This chart shows how effectively the company manages projects. Profitability depends on scale: the more trials they conduct simultaneously, the more efficiently they use their resources.
%20Chart%20ICON%20Public%20(ICLR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ICON-Public-ICLR&v=1772581306740 "Company Profit Per Employee (in thousands of dollars) Chart ICON Public (ICLR)"){kind=icon}
Profit per employee (in thousands of dollars) in the market segment - Pharma tests
ICON (ICLR) is one of the world's largest CROs (Contract Research Organizations), a company conducting clinical trials. This chart shows the benchmark for "Pharma Testing." For this "B2B service," the benchmark is moderate. It's a "people-based business," and the profit per employee (scientist, manager) depends on the scale and effectiveness of project management.
%20in%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-tests&v=1772581306771 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma tests")
Profit per employee (in thousands of dollars) for the market as a whole
ICON Public is a global contract research organization (CRO) providing outsourced development services to the pharmaceutical industry. This chart, reflecting the value of human capital, illustrates their business model. Revenue is generated through the expertise of thousands of scientists and physicians who manage clinical trials for clients worldwide.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772581306789 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ICON Public (ICLR)
ICON is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services. This chart illustrates the value of intellectual capital in the pharmaceutical industry. Its high revenue per employee is the result of the work of thousands of scientists and physicians who manage complex global studies for pharmaceutical giants.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ICON-Public-ICLR&v=1772581306815 "Sales chart per company employee ICON Public (ICLR)"){kind=icon}
Sales per employee in the market segment - Pharma tests
ICON (ICLR) is one of the world's largest contract research organizations (CROs) supporting clinical trials. Like Medpace, it is a service business, selling the expertise of thousands of scientists. This chart demonstrates the effectiveness of their global model, comparing how their staff generates revenue compared to other players in the pharmaceutical testing sector.
Sales per employee for the market as a whole
ICON is one of the world's largest think tanks for the pharmaceutical industry. As a contract research organization (CRO), they manage large-scale and complex clinical trials for Big Pharma. This chart shows the high revenue generated by their huge team of scientists, doctors, and project managers.
Short shares by company, segment and market as a whole
Shares shorted by company ICON Public (ICLR)
ICON (ICLR) is one of the world's largest contract research organizations (CROs). Like Medpace, they help pharmaceutical companies conduct clinical trials, but on a much larger scale. This chart measures bearish sentiment. A rise in shorts could signal concerns about a general slowdown in R&D in the pharmaceutical sector or difficulties with integration following major acquisitions.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ICON-Public-ICLR&v=1772581306923 "Short Shares Chart for the Company ICON Public (ICLR)"){kind=icon}
Shares shorted by market segment - Pharma tests
ΠΠ°Π³ΡΡΠ·ΠΊΠ°...
Shares shorted by the overall market
ICON Public (ICLR) is one of the world's leading contract research organizations (CROs), managing complex clinical trials for pharmaceutical companies. This chart shows the overall level of pessimism. When fears rise, investors look to ICLR to see if Big Pharma and biotech will continue to invest aggressively in R&D, or if they will freeze research budgets for fear of a recession.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ICON Public (ICLR)
ICON is one of the world's largest contract research organizations (CROs). They manage complex clinical trials for pharma giants. This chart reflects how confident investors are (above 70) in a stable flow of R&D orders, or (below 30) how concerned they are about the risks of biotech budget cuts or failed post-M&A integrations.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ICON-Public-ICLR&v=1772581307018 "RSI 14 indicator chart for the company's stock ICON Public (ICLR)"){kind=icon}
RSI 14 Market Segment - Pharma tests
ICON plc is one of the world's largest contract research organizations (CROs). They provide outsourced clinical trial development and execution services for the pharmaceutical and biotech industries. This chart measures the overall momentum in the CRO sector. It helps investors understand whether ICON's performance is part of a broader industry trend or an outlier.
RSI 14 for the overall market
ICON plc is one of the world's largest contract research organizations (CROs), providing clinical trial outsourcing services to pharmaceutical and biotech companies. Their business serves as a barometer of R&D activity. This market sentiment indicator shows how easily biotech companies can raise capital. Market euphoria means an influx of capital into R&D and an increase in orders for ICON. Panic dries up funding.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ICLR (ICON Public)
ICON Public is one of the world's largest contract research organizations (CROs), managing clinical trials for pharmaceutical companies. This chart reflects the collective opinion of analysts. Their forecasts are based on the size of the order backlog, demand for research outsourcing, and the successful integration of acquired assets (like PRA Health).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ICLR-ICON-Public&v=1772581307086 "A chart showing analyst consensus forecasts for the expected stock price. ICLR (ICON Public)"){kind=icon}
The difference between the consensus estimate and the actual stock price ICLR (ICON Public)
ICON is one of the world's largest CROs (contract research organizations), helping pharma and biotech companies conduct complex clinical trials. This chart shows the difference between the consensus estimate and the price. It reflects analysts' belief in the long-term trend toward R&D outsourcing and ICON's leadership in this area.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ICLR-ICON-Public&v=1772581307128 "A chart showing the difference between the consensus forecast and the actual stock price. ICLR (ICON Public)"){kind=icon}
Analyst consensus forecast for stock prices by market segment - Pharma tests
ICON is one of the world's largest contract research organizations (CROs). It helps Big Pharma and biotech companies conduct large-scale clinical trials. This chart shows analysts' overall expectations for the entire pharma testing sector. It reflects whether experts believe global R&D budgets in medicine will grow.
Analysts' consensus forecast for the overall market share price
ICON is one of the world's largest CROs (contract research organizations), helping pharmaceutical companies conduct clinical trials. Their clients include big pharma and biotech. Market expectations, as shown in this chart, influence R&D budgets. If investors are pessimistic, biotechs have a harder time raising funds, reducing demand for ICON's services.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ICON Public
ICON is one of the world's largest contract research organizations (CROs). Like Medpace, they manage clinical trials for pharmaceutical companies, but on a much larger, global scale. This chart is an indicator of R&D outsourcing. It reflects a global trend in which big pharma is increasingly outsourcing clinical trials to giants like ICON.
AKIMA Market Segment Index - Pharma tests
ICON is a CRO (contract research organization) titan, which (after acquiring PRA Health) became a global leader in R&D outsourcing for pharmaceutical companies. This aggregate metric evaluates companies. The chart shows the sector average. This benchmark: how does ICON's large-scale (and global) service model differentiate it from the average CRO competitor?
The AKIM Index for the overall market
ICON is one of the world's largest contract research organizations (CROs). The company helps pharma and biotech giants conduct clinical trials. This chart, showing the average market figure, provides context. It helps assess how ICON, whose business relies on R&D budgets in the defense sector, fits into the overall macroeconomic picture.
